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The last decade has seen an exponential growth in the quantity of clinical data collected nationwide, trig-
gering an increase in opportunities to reuse the data for biomedical research. The Vanderbilt research
data warehouse framework consists of identiﬁed and de-identiﬁed clinical data repositories, fee-for-
service custom services, and tools built atop the data layer to assist researchers across the enterprise.
Providing resources dedicated to research initiatives beneﬁts not only the research community, but also
clinicians, patients and institutional leadership. This work provides a summary of our approach in the
secondary use of clinical data for research domain, including a description of key components and a list
of lessons learned, designed to assist others assembling similar services and infrastructure.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Over the last decade, the transition from paper medical records
to electronic clinical systems has been accelerated by a national
emphasis on modernizing our health care infrastructure. Legisla-
tive initiatives, such as the Health Information Technology for Eco-
nomic and Clinical Health (HITECH) Act of 2009 [1], which includes
monetary incentives (and ultimately penalties), requires providers
to show ‘‘meaningful use’’ of certiﬁed electronic health records
(EHRs). This resulted in a signiﬁcant growth in the amount of
clinical data being collected. The transition from paper to elec-
tronic clinical systems has also created new opportunities for
secondary use of clinical data in biomedical research. Rapid cohort
identiﬁcation, quality of care assessment, comparative effective-
ness research, data privacy and de-/re-identiﬁcation research,
phenotyping methodology and predictive modeling represent a
handful of areas where ready access to clinical data for research
endeavors is beginning to make a real impact at academic medical
centers across the country.
In 2006, responding to national trends, the American Medical
Informatics Association (AMIA) compiled a set of recommenda-
tions [2] that deﬁned challenges and stressed beneﬁts of re-
search-driven secondary use of clinical data. MacKenzie et al. [3]surveyed 35 Clinical and Translational Science Award (CTSA) orga-
nizations and the NIH Clinical Center in 2008 and 2010, reporting a
positive trend for institutional development, management and uti-
lization of integrated data repositories to support the research
enterprise. Primary obstacles reported in the 2010 survey included
data quality and standards issues related to assembling a common
repository from multiple systems, sustainable funding to support
infrastructure and operations, and meaningful data access services
provided to research teams. In 2012, Murphy et al. [4] surveyed 17
institutions and observed a signiﬁcant increase in the clinical
repositories used for research since 2007. In 2013, Embi et al. [5]
surveyed clinical research informatics (CRI) papers published in
scientiﬁc journal and conference proceedings from 2009 to 2013
and observed six common themes: (1) clinical data reuse for re-
search; (2) data and knowledge management, discovery and stan-
dards; (3) researcher support and resources; (4) participant
recruitment; (5) patients/consumers and CRI; and (6) policy, regu-
latory and ﬁscal matters. Large-scale, integrated data repositories
are foundational for work in many of these areas, resulting in a
growing number of academic medical centers assembling big data
programs to support the local research enterprise. Examples in-
clude Intermountain Healthcare [6], Massachusetts General Hospi-
tal [7], the Mayo Clinic [8], Columbia University Medical Center [9]
and Stanford Medical Center [10]. Data exploration tools such as
i2b2 [11] and Harvest [12] have been designed to directly support
researcher data inquiry needs, though a combination of tools and
human expert support are typically needed for optimal enter-
prise-wide researcher support.
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Center (VUMC) began a series of clinical informatics initiatives
[13,14] resulting largely in the elimination of paper medical re-
cords by 2004 [15]. Vanderbilt’s current clinical framework con-
sists of a variety of software systems, both off-the-shelf
commercial solutions and applications developed in house. A cen-
tralized transactional messaging engine called the Generic Inter-
face Engine (GIE) manages communication and information
exchange between systems. This early adoption and integration
of electronic clinical information systems have had signiﬁcant im-
pact in the domains of clinical care, patient safety, provider
accountability, and improved documentation [16–19]. The end re-
sult of our early launch and continuously evolving clinical systems
is an information-rich environment covering 2 million patients,
with longitudinal records spanning more than a decade.
For a long time at Vanderbilt, the EHR system (StarPanel) and an
enterprise data warehouse (EDW) were the two main repositories
of clinical and billing data. The need for a dedicated research
framework emerged because common data repositories represent
only half of the solution. Researchers need secure and reliable ac-
cess to data programmers and/or self-service tools to query data,
and must understand the meaning and structure of data elements
to avoid making naïve assumptions. This paper provides a descrip-
tion of Vanderbilt’s approach to secondary use of clinical data and
presents a set of practical ’’lessons learned’’ that could prove useful
for other institutions considering assembling similar infrastructure
and data access services.2. Methods
2.1. Overview
The Ofﬁce of Research Informatics (ORI) leads Vanderbilt initia-
tives involving the secondary reuse of clinical data for research.
Working with faculty across the Vanderbilt Departments of Bio-
medical Informatics (DBMI) and Biostatistics, ORI contributes reg-
ularly to the support of new methods development. By providing
data and infrastructure support to nationally recognized research
initiatives in natural language processing (NLP) [20], privacy and
security [21], data mining and pattern discovery based on probabi-
listic machine learning [22], and personalized medicine [23], ORI
contributes to building and reﬁning enterprise systems that rapidly
inform and improve upstream clinical enterprise processes.
The ORI research support enterprise can be loosely described as
a centralized collection of tools and services that are available to all
research teams. We use an iterative model for tool development
where the lessons learned are constantly and rapidly incorporated
as new functionality. The hierarchical evolution enables tool sup-
port to be made available to research teams at no cost. Services,
both technical and administrative, are available to research teams
at low cost under a fee-for-service pricing model with billing
through a centralized Vanderbilt Core Ordering and Reporting
Enterprise System (CORES) [24]. Leveraging tools and services in
an equitable fashion and asserting a fee-for-service model allows
us to satisfy researchers’ need for data access and to provide sus-
tainable funding for the research enterprise, two of the main obsta-
cles observed by MacKenzie et al. [3] at other institutions. Tools
and service-level requests rely on a large-scale research data ware-
house, which we have assembled through connectivity with our
EDW team, ancillary clinical care systems throughout the medical
center, registries, and other peripheral support systems. Since we
depend on other systems for data, we face similar challenges as
other institutions with regard to information quality and standards
[3]. To mitigate these hindrances as much as possible we process,
transform, organize and optimize our data for use across multipletools and platforms. We maintain a fully de-identiﬁed research
data warehouse called the Synthetic Derivate (SD) and a fully iden-
tiﬁed research data warehouse called the Research Derivative (RD).
The RD can be thought of as a mirror of all of the clinical data col-
lected at VUMC, but organized for research. The SD represents a
‘‘de-identiﬁed’’ version of the RD and is linked to an anonymized
DNA biobank (BioVU) [25]. Fig. 1 below shows an overview of
the clinical and research informatics environment at Vanderbilt.
The speciﬁc sections (marked A–F) will be described in more detail.
2.2. Clinical enterprise
The epicenter of Vanderbilt’s network of clinical information
systems (Fig. 1 Sec. A) is a modern, web-based, EHR interface called
StarPanel [15]. StarPanel facilitates clinical note generation, pro-
vider and user communication, and integrates patient speciﬁc data,
in real-time, from a variety of clinical care systems such as the lab-
oratory information systems, the inpatient registration system, the
provider order entry system, a nursing documentation system, a
barcode medication administration system, and various other
ancillary systems like anesthesiology, cardiology, radiology, and
trauma. While StarPanel has been carefully architected for rapid
response time, and is designed to support the daily workﬂow of
clinical care teams, it is not well suited for efﬁciently querying or
extracting data across populations of patients. This limits its use-
fulness for research applications. In addition to StarPanel, most
clinical data within Vanderbilt clinical systems are captured and
stored in an EDW. As is the case with many institutional EDWs,
data capture and organization is largely driven by business intelli-
gence/reporting needs and long-term preservation goals. These
business-driven architectures are usually not designed for support-
ing large research communities. EDW leaders and professional
support personnel are also typically more concerned with institu-
tional program goals (e.g. large-scale quality initiatives) than sup-
porting individual research projects. Access and utilization of EDW
data sources by independent research teams can be challenging
without expert guidance.
2.3. Research data warehouse: the identiﬁed data layer (RD)
The RD (Fig. 1 Sec. B) is a database of clinical and administrative
data that is well suited for research, quality improvement, and
institutional projects requiring rapid, efﬁcient extraction of clinical
data on a deﬁned cohort using speciﬁc tests or phenotypes as
inclusion criteria to deliver identiﬁed datasets, recurring reports,
and up-to-date counts of subjects meeting the inclusion criteria.
The bulk of structured clinical data comes into the RD daily via
the EDW, which has well established Extract, Transform and Load
(ETL) pipelines from multiple sources of patient registration, clini-
cal and billing information. In many cases, though, the EDW stor-
age mirrors the production databases of the source systems,
resulting in both record attribute redundancy and value limitations
from a clinical perspective. To address this issue, we created our
own ETL layer. The RD uses the same coding schemes used by
the VUMC clinical systems and is an aggregation of different stan-
dards. As such, structured medication information uses the First
Databank (FDB) coding standard, diagnoses use the International
Classiﬁcation of Diseases (ICD-9), and medical services and proce-
dures use the Current Procedural Terminology (CPT). Our commer-
cial laboratory information management system (LIMS) uses 2
letter combinations for lab codes, which our StarPanel EHR then
maps to VUMC speciﬁc lab short names, thus allowing ﬂexibility
in situations where source vendor systems are replaced. The RD
system uses laboratory short names as identiﬁers. Electronic notes
and reports known as StarDocuments are stored as unstructured
data via plain text documents. All note data are assembled in the
Fig. 1. Vanderbilt clinical and research enterprise.
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record number, timestamp, document type, and document name).
Documents are easily mined using simple keyword or regular
expression searches. We use MedEx [26] for medication extraction
from past medical histories, medication lists, prescriptions and re-
ﬁlls, and problem lists. Semi-structured data are more granular and
generally consist of multiple-answer forms, known in StarPanel as
StarForms. Data from StarForms are parsed and stored in the RD as
key-value pairs. More information on clinical documentation types
available within Vanderbilt clinical systems is available elsewhere
[19,27]. StarDocuments and StarForms are loaded weekly in the
RD, after ORI-constructed programs perform careful cleaning pro-
cedures (e.g. removing html tags, extracting clinical note sections
such as family history and problem lists, and removing duplicated
elements). The RD database is stored on a secure IBM Netezza
1000-24 [28] database server housed in the Vanderbilt Data Cen-
ter. The database is fully compliant with the administrative, phys-
ical, and technical provisions of the Health Insurance Portability
and Accountability Act of 1996 (HIPAA) Security and Privacy Rules,
and operates with oversight from the Vanderbilt Institutional Re-
view Board (IRB).
2.4. Research data warehouse: the de-identiﬁed data layer (SD)
Many secondary use research projects can be performed in a de-
identiﬁed environment, and in so doing minimize privacy risks to
individuals. By removing potential identiﬁers (deﬁned in the
safe-harbor provision of HIPAA [29]) before storing in a similar
data architecture to the RD, we have established the SD as a sepa-
rate research-ready data warehouse (Fig. 1 Sec. C). De-identiﬁca-
tion methods include: (a) medical record numbers (MRNs) are
replaced by research unique identiﬁers, generated by a one-way
hash from the MRN; (b) dates are shifted backwards by a constant
within each patient, a deterministically calculated number of days
between 0 and 364, obfuscating the true service dates while pre-
serving the time dependence between service dates, and (c) free
text notes are stripped of the remaining protected health informa-
tion (PHI) identiﬁers via De-ID [30], a product of Data Safety Soft-
ware. Because data are de-identiﬁed, research protocols using only
the SD as a data source are often evaluated as non-human subjectprotocols by the IRB. Nevertheless, access to the SD requires
researchers to provide evidence of IRB approval or determination
and a signed data use agreement. The SD is linked to an anony-
mized DNA biobank (BioVU) [25], which includes de-identiﬁed ge-
netic biosamples (DNA) collected from leftover clinical blood
samples. Genotyping data obtained from a variety of platforms
(e.g. Inﬁnium HumanExome BeadChip, HumanOmni5-Quad, and
Human1M). The combination of DNA samples linked to de-identi-
ﬁed clinical data provides a powerful resource for genomic re-
search [31–35], while the SD alone can support a substantial
breadth of research; the only substantial limitation includes
time-sensitive epidemiological studies [36,37]. Dates are shifted
in the SD as part of the de-identiﬁcation process, so although time
intervals within each medical record are preserved, cohort data
cannot be linked to temporal events such as epidemics or natural
disasters. The SD and BioVU methodologies have previously been
described in detail [25].
2.5. Supporting informatics and biostatistical methods development
Building and maintaining large-scale, research-oriented data
repositories requires methods and experts from numerous spe-
cialty domains. Data architecture and technical infrastructure spe-
cialists, medical experts, and clinical workﬂow experts (Fig. 1 Sec.
D) are all needed to ensure proper contextual understanding of the
data retrieved and stored in the research data warehouse. Infor-
matics professionals with conceptual and applied knowledge of
natural language processing are required to turn unstructured
clinic notes and medication orders into structured information that
can be easily stored and readily queried, through initiatives like
MedEx [26]. For de-identiﬁed data warehousing initiatives like
the SD, informaticians and computer scientists with knowledge
and understanding of patient de-identiﬁcation and re-identiﬁca-
tion risks are critical. Privacy and ethics experts are critical for in-
put and assistance with governance and policy [21,37–41]. Finally,
predictive modeling and machine learning experts are required to
convert data into actionable information to feed forward into re-
search protocols or into improvements in workﬂow within the
clinical enterprise. Vanderbilt has strong informatics and biostatis-
tics departments, resulting in availability of faculty with needs for
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search [27,42]. These relationships are synergistic. In exchange
for access to large datasets required to build and maintain their
personal research programs, these experts are happy to participate
in SD/RD formative planning and iterative exercises designed to
build and improve data warehousing services [20,21,38,42,43].
2.6. Translational use for the clinical enterprise
Knowledge dissemination and translation into clinical practice
are the ultimate goals of informatics and biostatistical research.
Initiatives supported by ORI (Fig. 1 Sec. E) have eventually become
standard practice in clinical workﬂow. The Pharmacogenomic Re-
source for Enhanced Decisions in Care and Treatment (PREDICT)
[23] is a prominent personalized medicine initiative that ﬁrst lev-
eraged BioVU genotyping and SD phenotyping information to facil-
itate predictive modeling that would ultimately change prescribing
practices at the bedside. Quality improvement initiatives at VUMC
have utilized the RD to efﬁciently measure patient outcomes
resulting in the implementation of new clinical care processes.
The most recent effort is an acute kidney injury (AKI) initiative that
leverages the RD to identify risk factors for AKI, and implement
new prescribing workﬂows in the computerized physician order
entry system.
2.7. The research enterprise
Building comprehensive research data warehousing assets is a
formidable task, but of little value to the larger research commu-
nity unless accessible in an equitable and approachable manner.
Our general approach (Fig. 1 Sec. F, Fig. 2) is to build: (1) self-ser-
vice tools available at no – or low – cost for researchers; and (2)
customized tools and data extraction services using a fee-for-ser-
vice agreement with researchers to sponsor ORI programmers
when existing self-service tools are not adequate to fulﬁll complex
use cases. In working with the researcher-sponsored complex use
cases, ORI programmers compile lessons learned and review meth-
ods that can later be abstracted and fed back into the no – or low –
cost offerings.
Two web-based applications provide researchers with ‘‘self-ser-
vice’’ access to the de-identiﬁed data warehouse: the Record Coun-
ter user interface (RC UI) and the SD user interface (SD UI). The SD
UI and RC UI share common query functionality for data elements
such as labs, medications, vitals, codes (ICD-9 and CPT) and regis-
tries such as the tumor registry. Users are able to generate ad hoc
queries and view approximate record counts in real-time. The pri-
mary difference between the two applications is that the RC UI al-
lows users to view only aggregated record counts (grouped by age,
race, and sex), while the SD UI provides aggregated counts and the
ability to save result sets, allowing review of record level data and
requests for DNA data from BioVU. Results obtained via the SD UIFig. 2. ORI data services model.can be exported in text (.txt) format for upload into biostatistics
programs or can be sent directly to an automatically generated
REDCap data mart. REDCap is web application that facilitates sur-
vey and database management in a secure manner and has been
described in detail in [44]. The SD UI can be accessed only by inves-
tigators who have completed an approval process and received IRB
permissions for use in their speciﬁc study and who have signed a
data use agreement. The RC UI is accessible to the entire Vanderbilt
community through our StarBRITE research portal [45] at no cost,
and is often used for hypothesis generation, study planning and
feasibility consideration.
Subject Locator is a web-based ‘‘self-service’’ tool that lever-
ages the RD to facilitate identiﬁcation of patients in the clinical
enterprise who meet basic requirements for study inclusion in
prospective studies and trials. Here, researchers leverage a tool
very similar to the RC query generator to select speciﬁc criteria
(e.g. labs, medications, vitals, ICD-9 and CPT codes) for use as
rough inclusion/exclusion criteria for their study. Researchers
also specify a set of clinics most likely to be effective for
recruiting patients, based on medical conditions and a priori
relationships with clinical providers. Study criteria and visit
information is cross-referenced on a daily basis. The resulting list
is provided to research teams for prospective consideration of
new participants. Within the application, users manage lists of
prospective subjects as they are investigated and potentially con-
tacted by research teams. Access to Subject Locator is available
to research teams working on individual projects that obtain
IRB approval to use the tool. Furthermore, Subject Locator
includes automated checks to ensure individual end-users have
‘‘key study personnel’’ designation within the Vanderbilt IRB
system for the particular study.
Researchers interface with the RD primarily through the Van-
derbilt Data Coordinating Center (VDCC) by way of fee-for-service
cohort extraction, custom algorithm development and project
management. A project manager veriﬁes research study IRB status,
and secures signed data use agreements as needed, and then works
with the RD engineers and investigators to reﬁne cohort deﬁnitions
and study design. To meet the needs of the project, the RD team
creates the dataset and delivers it to the requester in a secure
and agreed upon format using either a secure transfer server or
by uploading it into the requester’s REDCap project. A detailed ﬂow
diagram of the RD intake process and delivery is presented in Fig. 3
below.
3. Value proposition
At Vanderbilt, the usefulness of a dedicated infrastructure for
supporting the secondary use of clinical data for research is becom-
ing increasingly apparent for various stakeholders across the
enterprise.Fig. 3. RD request process.
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irrespective of their seniority level. Since its inception, the SD has
provided infrastructure and support for various research projects
that resulted in 87 papers published between 2010 and 2013
[21,23,26,27,32–37,39–42,45–115], with 61 ﬁrst authors from 18
different departments. The diverse range of topics studied and re-
ported in these papers (e.g. quality improvement, genetic associa-
tions (BioVU), pharmacogenomics, NLP, privacy, ethics, general
informatics methods research) illustrates the utility of the SD for
research purposes. The RD is a more recently developed resource,
and even though the research projects it has supported have not
yet matured into publications, it shows encouraging trends in
usage. Between September 2010 and August 2013, we received
102 requests for data from 72 different investigators from 21 dif-
ferent departments.
Patients can beneﬁt greatly from a large research data ware-
housing program through initiatives like personalized medicine,
clinical trial opportunities, and quality improvement programs
that rapidly translate research into practice to transform clinical
care. Centralized data warehousing resources also enable tighter
data control and enhanced security and privacy of patient data.
For clinicians, translational projects drive opportunities for
optimization of workﬂow with just-in-time information, enabling
evolution of clinical practice through initiatives like personalized
medicine.
In a strong research environment, with data and tools readily
available, institutional leadership beneﬁts from increased grants
and contracts. Strong institutional assets also provide an advantage
in recruiting new faculty and in enhancement of reputation for the
center.
Finally, quality improvement and research often have similar
needs for longitudinal data to create 360-degree views of single pa-
tients, as well as cohort identiﬁcation; having a multi-purpose re-
source with a lean cost structure beneﬁts both endeavors.4. Lessons learned
We present below a series of lessons learned during the process
of creating infrastructure, policy and organizational support for re-
search data warehousing which are closely in line with the CRI
trends observed by Embi et al. [5].
4.1. Leveraging clinical enterprise data sources
The primary role of clinical users is caring for patients, and tech-
nology must support and complement this mission [116]. As a di-
rect consequence, the resulting data might be incomplete from a
research standpoint, in different formats or missing altogether,
and need to undergo a careful cleanup and transformation process
before they can be used for research. Incompleteness, inconsis-
tency, and inaccuracy are major challenges also observed at other
institutions [9,117] and in industry [118]. Understanding the clin-
ical signiﬁcance of the data and the way they are coded in clinical
settings is a major and necessary task in reusing clinical data. Ulti-
mately, it is the responsibility of the research enterprise to process
and maintain data in a meaningful and scalable manner.
4.2. Research data warehouse framework
In an environment where grant funding is increasingly compet-
itive, researchers need quick, reliable and reproducible cohort
identiﬁcation mechanisms and the capacity for retrospective clin-
ical research. Regulatory issues and policy around access to clinical
data are often complex, and investigators sometimes need assis-
tance with understanding privacy requirements. The availabilityof research and informatics support teams meets this need and
eases investigator burden by providing speciﬁc data expertise
and extraction skills. Data sharing also facilitates the development
and validation of informatics methods including NLP, de-identiﬁ-
cation approaches and large-scale phenotyping. Collaborative ini-
tiatives such as the Electronic Medical Records and Genomics
(eMERGE) initiative [66], the Strategic Health IT Advanced Re-
search Projects (SHARPn) framework [7] or the Stanford Transla-
tional Research Integrated Database Environment (STRIDE)
platform [10] promote sharing and testing of new methodologies
in diverse clinical populations and environments, which ultimately
strengthens the national research informatics enterprise.
4.3. Supporting informatics and biostatistical methods development
The anatomy of the research domain at leading academic med-
ical centers is extremely complex, and successful projects often re-
quire a diverse range of expertise during different phases of their
life cycles. While rigorous and organized documentation of the dif-
ferent methods, algorithms and data is a necessity, the research
enterprise relies heavily on human experts to help build these
repositories and ultimately advance the research enterprise. Devel-
oping and maintaining a team with deep clinical and research do-
main knowledge across the vast array of areas of study, though
necessary, present signiﬁcant challenges.
4.4. The research enterprise
Self-service tools are a viable solution for the research enter-
prise because they effectively scale for increasing data demand.
The ultimate measure of utility of these tools is the ability to efﬁ-
ciently complete studies and projects as well as user satisfaction.
Establishing and engaging a user group community for software
tools early in the development process is ideal. User groups are
invaluable to all the parties involved for face-to-face help, ques-
tions, instruction, and feedback. Building conﬁdence and under-
standing of both the data and self-service tools empowers the
end user, and relieves pressure on the internal support team. Build-
ing such a community after years into the project is not an easy
task, but once the research community has become familiar with
the tools available, they will generate an increasing demand and
requests for more functionality. Visualization and graphical tools
breed ideas and creativity to assist investigators in understanding
and seeing trends within the data.
Human-support is also necessary for assisting investigators in a
number of ways. The typical researcher from an academic medical
department may not have sufﬁcient awareness of institutional data
to formulate a question that can be easily translated into an action-
able cohort identiﬁcation or data retrieval request from data pro-
grammers. Researchers are often unaware of the complexity in
clinical data systems, how and when data are captured, and for
what purpose. For instance, changes in diagnostic and billing
codes, clinical unit names, laboratory test names, and other param-
eters occur over time; algorithms used to extract data on a cohort
over time must therefore account for this complexity. Producing an
optimal dataset often requires multiple iterations of cohort deﬁni-
tion and algorithm reﬁnement with clinical users, software devel-
opment staff, and database administrators. Leveraging the right
resources ultimately results in large time and cost savings for the
researcher as well as reproducible and accurate results.5. Conclusion
Secondary use of clinical data can play a critical role at large
academic medical centers. Building a dedicated research infrastructure
I. Danciu et al. / Journal of Biomedical Informatics 52 (2014) 28–35 33at Vanderbilt has enabled us to better serve the research commu-
nity, advance informatics and biostatistical methods development,
and ultimately use evidence-based results to change clinical
practice.
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